our company

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Andrea_Puletto — Thu, 28 Nov 2024 08:53:01 +0000

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Veronique Toully, Sustainability, Corporate Affairs and Risks

Andrea_Puletto Thu 28/11/2024 - 09:53

Today, I am proud to announce that our new carbon emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi), a significant achievement that underscores our commitment to sustainable impact and our dedication to reducing our environmental footprint.

Specifically, our validated net-zero targets aim to reduce absolute scope 1, 2 and 3 greenhouse gas (GHG) emissions by 90% by 2045 (from our 2019 baseline), ensuring we are aligned with the latest climate science to meet the goals of the Paris Agreement and achieving net-zero before 2050.

This is an important step in a collection of actions we are taking to minimise our environmental footprint. We have started and will continue to embed green aspects and considerations from the very start of the creation of each of our medicines. And we are working closely with our suppliers to set and validate science-based targets for carbon emissions, supporting their shift towards a low-carbon economy.

At ��ֳ� we understand the intrinsic link between the health of people and the planet and believe that the pharmaceutical industry has a critical role to play. Healthcare systems have a large carbon footprint, accounting for an estimated 4.4% of global greenhouse gas emissions, and of those about 1/3 comes from medicines.

We are committed to demonstrating that business success and environmental stewardship are not mutually exclusive but rather mutually reinforcing. Setting science-based targets ensures our growth is sustainable by reducing costs, boosting investor confidence and enhancing our competitiveness and innovation. Sustainability is at the core of our operations, driving us to positively impact society and secure ��ֳ�'s long-term success.

This validation by the SBTi is the testament to the collective work and achievements in our environmental sustainability journey so far. It represents a pivotal moment, elevating our commitment towards a more sustainable future. Together, with the support of our colleagues, partners and stakeholders, we can achieve our vision of creating a healthier, more sustainable world.

“Climate change is one of the biggest challenges facing our planet today, causing devastating impacts such as extreme weather events, sea level rise, and loss of biodiversity. Achieving net-zero emissions is crucial in mitigating the climate crisis. We firmly believe that it is our responsibility to lead by example and take concrete steps towards a sustainable and resilient future. By setting ambitious, science-based targets, we aim to significantly reduce our carbon footprint and contribute to global efforts to mitigate the climate crisis.” Our CEO, Jean-Christophe Tellier, said. 

We invite you to join us on our journey toward a sustainable future. Stay connected and learn more about our initiatives by following me and ��ֳ� on LinkedIn and visiting our website at Reducing emissions | ��ֳ�.

about ucb

216 Likes

��ֳ� Belgium: A global hub of healthcare innovation

Andrea_Puletto — Wed, 20 Nov 2024 14:22:27 +0000

��ֳ� Belgium: A global hub of healthcare innovation

Jiri Keirsse, Public Private Partnerships & Innovation Strategy

Andrea_Puletto Wed 20/11/2024 - 15:22

Recognized by the European Innovation scoreboard, Belgium has positioned itself as a powerhouse in healthcare and pharmaceutical innovation, with a unique blend of academic rigor and industry expertise driving its success. This thriving ecosystem is characterized by strong collaboration between leading research institutions and pharmaceutical companies, setting Belgium apart on a global level. The partnership between ��ֳ� and KU Leuven, a renowned research institution, is a prime example of the country's collaborative spirit. With the potential to span early discovery to clinical proof of concept we are working to advance healthcare innovation, addressing unmet patient needs, and solidifying Belgium’s influence in the global healthcare landscape.

Belgium’s academic landscape is home to institutions like KU Leuven, which are not only centers of education but international communities where innovative research forms the basis of all their academic programs – they act as a catalyst and connector for innovation and scientific discovery. Like ��ֳ�, KU Leuven is at the forefront of cutting-edge research. They play a pivotal role in translating academic insights into practical healthcare applications with a keen focus on moving from ‘science to business’. That makes them a great partner for ��ֳ�; from unlocking the secrets of chemicals, cultivating the promises of pharmaceuticals and expanding into biologics, peptides and gene therapy, we at ��ֳ� are on a mission to continuously innovate. We also recognize that we cannot solve the world’s healthcare challenges alone, and so we know the value gained from collaboration across disciplines, geographies and stakeholders. Innovation has no boundaries, and real breakthroughs will result from the use of new technologies and trust-based collaboration and partnerships.

At the core of Belgium’s healthcare success is its collaborative ecosystem. The partnership between ��ֳ� and KU Leuven exemplifies how academia and industry are incentivized to work hand in hand to push the boundaries of knowledge and innovative science. The culture of collaboration is stimulated by open conversations, translating from the world of academia to drug development. Building a connection based on similar motivations develops an organic relationship between the two parties, and in turn creates the best environment for collaboration and partnerships.

The healthcare innovations born from Belgium's collaborative efforts have far-reaching impacts beyond its borders. Developments made in Belgium are being adopted worldwide, driving improvements in patient outcomes and setting new standards in the pharmaceutical industry. As the healthcare landscape continues to evolve, Belgium remains well-positioned to spearhead change in innovation. The future promises even stronger academic-industry collaborations, with emerging trends pushing the boundaries of scientific discovery. Belgium’s long-term vision as a hub of healthcare innovation is anchored in its commitment to fostering partnerships that fuel ongoing advancements. Through this sustained collaboration, Belgium will continue to play a vital role in shaping the future of global healthcare.

Belgium’s healthcare innovation ecosystem, driven by collaborations between ��ֳ� and KU Leuven, is a powerful force in the global pharmaceutical industry. The country’s continued commitment to partnership and innovation ensures its influence will only grow, leading to new breakthroughs and closing the gap of unmet needs globally.

We recently spoke with Bart Geers, an Investment Manager from KU Leuven, Research & Development about innovation and the need for collaboration and partnerships across academia and the pharmaceutical industry. Watch the video to learn more.

innovation

Science innovation our company

199 Likes

Introducing Lissiah Taylor Hundley, Head of DE&I at ��ֳ�

Andrea_Puletto — Tue, 11 Jun 2024 13:55:27 +0000

Introducing Lissiah Taylor Hundley, Head of DE&I at ��ֳ�

Chiara Montecucco, Global Communications

Andrea_Puletto Tue 11/06/2024 - 15:55

We sat down with Lissiah Taylor Hundley, who recently joined ��ֳ� as Global Head of Diversity, Equity & Inclusion (DE&I).

Lissiah: With 27 years of experience in DE&I leading international teams, I’m passionate about equal rights and committed to driving meaningful change. As a survivor of stage 4 cancer, I’ve experienced healthcare disparities firsthand, which further deepened my dedication to enhancing DE&I. This is also what drew me to ��ֳ�, a company that supports diversity and inclusion and that can make a difference in improving equity in the communities around us.

��ֳ�: Can you share your initial experience at ��ֳ�?

Lissiah: It’s been amazing! In just a few months, I’ve seen the company’s commitment to DE&I. My approach has been one of balance between listening, learning, and starting to see where to implement strategic changes. I focus on ‘the 4 Ps’ - People, Patients, Products, and Partners - and I follow my deep belief that diversity drives innovation, growth and sustainability for the future.

��ֳ�: How do you view the current state of DE&I, beyond ��ֳ�?

Lissiah: It’s challenging, especially with political climate changes and polarization of the public opinion. However, I remain hopeful and passionate. There are many supportive organizations and engaged teams and talents committed to DE&I, both within and outside ��ֳ�. I believe in the power of exchange and collaboration, so engaging with these groups is therefore key to ensure the inclusivity of all different perspectives.

��ֳ�: What impact do you hope to make at ��ֳ�?

Lissiah: I hope to have DE&I intimately embedded in all that we do. Systemic change is important. With this we can drive change in DE&I initiatives within ��ֳ� and the broader industry. With the company’s support, I’m optimistic about creating a more equitable and inclusive environment that understands, respects and celebrates diversity.

��ֳ�: Any specific examples?

Lissiah: I want to ensure that our people mirror the patients and the communities we serve, so we partner closely with our Talent Acquisition team to support our diversity recruitment practices and ensure that all talent has an equitable hiring experience. I also seek to have more diverse patients in our clinical trials, so the DE&I team supports the business as they look to engage differently in diverse communities, work with external partners who have close connections to diverse patients and ensure we’re building trust in those communities as well. I also partner with the business to educate our teams so that they know how to connect with underrepresented groups and understand the cultural nuances that may play a role in how they trust and engage with us.

��ֳ�: Lissiah, thank you for sharing your journey with us. We look forward to seeing the impact you’ll have at ��ֳ� and in the larger DE&I space.

about ucb

DEI our company about ��ֳ� Diversity equity and inclusion

229 Likes

our company

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Leave a Comment

��ֳ� Belgium: A global hub of healthcare innovation

Leave a Comment

Introducing Lissiah Taylor Hundley, Head of DE&I at ��ֳ�

Leave a Comment

our company

������ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

Leave a Comment

������ֳ� Belgium: A global hub of healthcare innovation

Leave a Comment

Introducing Lissiah Taylor Hundley, Head of DE&I at ������ֳ�

Leave a Comment

��ֳ� net-zero targets validated by the Science Based Targets initiative: a critical step in our sustainability agenda

��ֳ� Belgium: A global hub of healthcare innovation

Introducing Lissiah Taylor Hundley, Head of DE&I at ��ֳ�